First Patient Enrolled in Ph 1a/b Study of PRMT5 Inhibitor GTA182 for MTAP-Deleted Solid Tumors November 26, 2024
First Patient dosed in Ph 1/2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid Cancers November 26, 2024
Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive NSCLC and Advanced NTRK-Positive Solid Tumors November 19, 2024
FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors November 19, 2024
IDEAYA Nominates IDE034, a B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen November 19, 2024
ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors November 19, 2024
Promising Preliminary Results of Investigator-Initiated Ph 1 Trial of Keytruda and LYMPHIRâ„¢ in Cancer Patients with Recurrent Solid Tumors Announced November 19, 2024
First patient dosed in Ph 1/2 study of Silmitasertib in children and young adults with R/R solid tumors November 12, 2024
IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Ph 1 Study in MSI-High Solid Tumors Announced November 5, 2024
FDA Clears IND Application for ATX-559 Ph 1 study in solid tumor patients with a focus on BRCA1/2-deficient breast cancer and MSI-H and dMMR solid tumors October 29, 2024
First Patient Dosed in Ph 1/2 Cell Therapy Trial of TAC101-CLDN18.2 for the Treatment of Claudin 18.2+ Solid Tumors October 22, 2024
AtomVie Global Radiopharma and Radiopharm Theranostics Partner to Develop and Manufacture 177Lu-BetaBart Radioantibody for Treatment of Multiple Solid Tumors October 22, 2024
First Patient dosed in Ph 1/2a Clinical Trial of BPT567 in patients with solid tumors October 22, 2024
US FDA issues Study May Proceed letter for the Pilot Study of Pidnarulex PD in Patients with Advanced Solid Tumors October 22, 2024
Nona Biosciences announced a strategic collaboration with OverT Bio to develop next-generation cell therapies for solid tumors October 15, 2024